GleamWall
中文EN

CTMX CytomX Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1501989 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-87.7%
TTM net income YoY-404.9%
TTM EPS YoY-329.6%
Revenue 3-yr CAGR-43.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-676.5%
Net margin-609.0%
FCF margin-363.6%
EBITDA margin—

Returns

ROE-43.6%
ROA-32.7%
ROIC (approx.)-46.3%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets21.9%
Debt / equity0.00x
Current ratio7.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.59x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.69M$1.42M$10.26M$663,000$5.96M$18.66M$50.92M$38.09M
R&D expense$16.48M$17.60M$19.24M$21.23M$15.30M$13.32M$18.87M$14.79M
SG&A expense$8.71M$7.60M$10.69M$7.36M$6.43M$6.62M$9.43M$5.62M
Operating income-$23.50M-$23.78M-$19.67M-$27.93M-$15.77M-$1.29M$22.62M$17.68M
Pretax income-$19.94M-$20.61M-$18.19M-$26.46M-$14.17M-$91,000$23.59M$18.94M
Income tax$61,000$60,000$59,000$54,000$58,000$63,000$62,000$62,000
Net income-$20.00M-$20.67M-$18.25M-$26.51M-$14.23M-$154,000$23.52M$18.88M
EPS (diluted)————————
Weighted avg. shares (diluted)219.11M218.94M177.27M—165.00M129.08M87.15M—
Balance sheet
Cash & equivalents$33.96M$17.22M$28.83M$12.67M$34.19M$49.04M$47.60M$38.05M
Short-term investments$314.02M$313.06M$317.88M$124.39M$109.44M$109.05M$32.28M$62.57M
Receivables$501,000$37.49M$646,000$2.01M$1.63M$1.87M$1.96M$3.10M
Current assets$356.05M$373.15M$353.10M$143.92M$149.22M$164.62M$86.63M$107.31M
PP&E, net$2.52M$1.08M$1.09M$1.30M$1.72M$1.95M$2.23M$2.47M
Goodwill$949,000$949,000$949,000$949,000$949,000$949,000$949,000$949,000
Total assets$364.68M$381.23M$359.36M$151.57M$158.25M$175.06M$98.50M$120.53M
Current liabilities$45.53M$39.86M$34.02M$46.62M$41.03M$39.22M$50.20M$85.77M
Total liabilities$79.79M$79.16M$39.41M$52.56M$50.87M$55.15M$73.45M$120.99M
Shareholders' equity$284.89M$302.07M$319.94M$99.01M$107.39M$119.91M$25.05M-$456,000
Shares outstanding———170.19M———80.10M
Cash flow statement
Operating cash flow$16.65M-$18.07M-$25.55M-$23.24M-$15.55M-$15.75M-$21.04M-$19.91M
Capital expenditure$589,000$0$0$201,000-$127,000$27,000$119,000$80,000
Free cash flow$16.06M-$18.07M-$25.55M-$23.44M-$15.42M-$15.78M-$21.16M-$19.99M
Investing cash flow-$3,000$5.95M-$192.78M-$14.42M$439,000-$76.36M$30.60M$15.13M
Financing cash flow$94,000$511,000$234.49M$16.64M$253,000$93.55M$0$2.25M
Stock-based compensation$2.84M$2.58M$4.71M$1.48M$1.38M$1.43M$2.01M$1.88M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.